Project Bioshield Act

Bio-Based Coatings Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Wednesday, December 21, 2022
Coffee, Organization, Charcoal, SE, Dulux, Sherwin-Williams, Glycerol, Tea tree oil, AkzoNobel, Diol, Employment, Reliance Industries, Solvent, Limonene, Caffeine, BASF, Transport, PPG, Growth, US, COVID-19, Alcohol, Strategy+Business, Paint, Cellulose, Ethanol, PPG Industries, Benjamin Moore & Co., BASF SE, Project Bioshield Act, VOC, Water, BHD, Geography, Acquisition, KCC, Fur clothing

The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term.

Key Points: 
  • The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term.
  • The various use include decorative paints, transportation, metal industrial coatings, industrial maintenance and protective, powder coatings, automotive refinish, wood coatings, marine coatings, coil coatings, packaging coatings.
  • VersaFlex is a Kansas â€" based protective coatings provider operating in bio based coatings market.
  • The bio-based coating market research report is one of a series of new reports that provides bio-based coating market statistics, including bio-based coating industry global market size, regional shares, competitors with a bio-based coating market share, detailed bio-based coating market segments, market trends and opportunities, and any further data you may need to thrive in the bio-based coating industry.

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, October 27, 2022
Office of Inspector General, U.S. Department of Health and Human Services, Smallpox, Development, NASDAQ, Private Securities Litigation Reform Act, Assistant, Vaccinia, Unitary state, U.S. Securities and Exchange Commission, European Medicines Agency, BARDA, MHRA, FDA, Medication, Webcast, Department, Xi, Biomedical Advanced Research and Development Authority, Research, COVID, U.S. Department of Commerce Office of Security, Investor relations, EMA, Human, Company, Patent, Form, Conference, Cowpox, Annual report, Phrase, GLOBE, Vii, Medicines and Healthcare products Regulatory Agency, Monkeypox, Documentation, SEC, Security (finance), Strategy, Department of Defence, Risk, Vaccine, Policy, Contract, Ix, IV, COVID-19, Infection, United Kingdom, Government, Vaccination, Project Bioshield Act, Human services, Exercise, SIGA Technologies

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, November 3rd, 2022.

Key Points: 
  • NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, November 3rd, 2022.
  • Participating on the call will be Dr.Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
  • Participants may access the call by dialing 1-844-826-3033 for domestic callers or 1-412-317-5185 for international callers.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.

ALLOSOURCE® ANNOUNCES AWARD FROM THE U.S. GOVERNMENT TO SUPPLY ALLOGRAFT SKIN FOR CRISIS PREPAREDNESS IN THE EVENT OF MASS CASUALTY BURN INCIDENTS

Retrieved on: 
Wednesday, October 12, 2022
United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Development, Government, Survivor, Explosion, Cartilage, Patient, Fascia, Allotransplantation, HHS, Research, Burns, Project, Burn, Rotation, ASPR, BARDA, Administration, Department, American Association, Association, Skin, Project Bioshield Act, Isolytic muscle contraction, FDA, American Association of Tissue Banks, Public sector banks in India, Surgeon, Medical imaging

The contract supports establishment of substantial inventories of donated skin for treatment of patients with burn injuries after mass casualty emergencies.

Key Points: 
  • The contract supports establishment of substantial inventories of donated skin for treatment of patients with burn injuries after mass casualty emergencies.
  • "It's a privilege to be selected to support the U.S. government in their emergency preparedness efforts."
  • For decades, skin allografts have played a vital role in the physical healing process of burn survivors.
  • In addition to supplying BARDA with PureSkin allografts, AlloSource will continue to offer skin allografts in multiple sizes and meshing formats to its surgeon customers.

SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, July 28, 2022
Contract, BARDA, Ix, Smallpox, Travel, Monkeypox, Policy, Company, Biomedical Advanced Research and Development Authority, Cowpox, Infection, Investor relations, Human, Research, EMA, Project Bioshield Act, Vii, U.S. Department of Commerce Office of Security, Virus, Vaccinia, GLOBE, Documentation, Monkeypox virus, Phrase, Patent, COVID-19, Conference, Webcast, Exercise, Human services, European Medicines Agency, Disease, FDA, Annual report, Risk, Vaccine, IV, Xi, Forward-looking statement, Development, Private Securities Litigation Reform Act, Office of Inspector General, U.S. Department of Health and Human Services, SIGA Technologies, NASDAQ, Assistant, Vaccination, Animal

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, August 4th, 2022.

Key Points: 
  • NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, August 4th, 2022.
  • Participating on the call will be Dr.Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dennis Hruby, Chief Scientific Officer.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.

SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

Retrieved on: 
Friday, July 15, 2022
U.S. Securities and Exchange Commission, Tumor microenvironment, Infection, Therapy, Risk, Project Bioshield Act, Smallpox, EMA, SIGA Technologies, Vaccine, Government, Ix, Office of Inspector General, U.S. Department of Health and Human Services, Research, CEO, Regulation of tobacco by the U.S. Food and Drug Administration, Xi, European Medicines Agency, Food, Private Securities Litigation Reform Act, Forward-looking statement, Vaccinia, Assistant, Policy, Exercise, NASDAQ, Biomedical Advanced Research and Development Authority, Vaccination, Physician, U.S. Department of Commerce Office of Security, Cowpox, Patient, Phrase, COVID-19, Partnership, Contract, Patent, Cancer, Human services, Monkeypox, GLOBE, Documentation, Development, IV, Annual report, FDA, Virus, Vii, BARDA, Pharmaceutical industry, NEJM

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX (tecovirimat) available for use with KaliVirs proprietary oncolytic vaccinia immunotherapy platform.

Key Points: 
  • NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX (tecovirimat) available for use with KaliVirs proprietary oncolytic vaccinia immunotherapy platform.
  • KaliVir is an innovator in the creation of oncolytic viral immunotherapies, and we are excited to enter into this collaboration with them, said Dr. Phil Gomez, CEO of SIGA.
  • This collaboration helps bring new levels of assurance to physicians, regulators, and especially patients receiving these promising investigational therapies.
  • We are pleased to announce this collaboration with SIGA Technologies, said Helena Chaye, Ph.D., J.D., CEO of KaliVir.

SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Retrieved on: 
Tuesday, July 12, 2022
Annual report, Development, Smallpox, US Foods, Office of Inspector General, U.S. Department of Health and Human Services, Xi, Biomedical Advanced Research and Development Authority, Patient, Policy, Private Securities Litigation Reform Act, Human, PHAC, Infection, Cowpox, IV, EMA, CEO, BARDA, GLOBE, Patent, National security, Public Health Agency, DND, Virus, Risk, Forward-looking statement, Ix, Public Health Agency of Canada, Exercise, Vaccination, Contract, Monkeypox, Vii, Orthopoxvirus, COVID-19, European Medicines Agency, Phrase, FDA, SIGA Technologies, NASDAQ, Vaccinia, Vaccine, Health Canada, Human services, Documentation, Government, Project Bioshield Act, Assistant, U.S. Department of Defense Strategy for Operating in Cyberspace, Research

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $28 million of procurement orders for oral TPOXX® (tecovirimat), including approximately $2 million for initial procurement by two new international jurisdictions and approximately $26 million for procurement by Canada, of which approximately $22 million is being procured by the Public Health Agency of Canada (PHAC) and approximately $4 million is being procured by the Canadian Department of National Defence (DND) under existing contracts. One of the new jurisdictions is in Europe, and the other new jurisdiction is in the Asia Pacific region.  

Key Points: 
  • NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $28 million of procurement orders for oral TPOXX (tecovirimat), including approximately $2 million for initial procurement by two new international jurisdictions and approximately $26 million for procurement by Canada, of which approximately $22 million is being procured by the Public Health Agency of Canada (PHAC) and approximately $4 million is being procured by the Canadian Department of National Defence (DND) under existing contracts.
  • In combination with the approximately $13 million PHAC order that was previously disclosed on the last investor call, PHAC and DND have ordered approximately $39 million of oral TPOXX (tecovirimat) this year.
  • To date this year, SIGA has received approximately $56 million of international orders for oral TPOXX (tecovirimat) from six jurisdictions, of which five are new customers.
  • The increase over the last two months in international orders of oral TPOXX (tecovirimat) reflects an initial public health reaction to the evolving monkeypox outbreak, said Phil Gomez, CEO of SIGA.

SIGA Technologies Receives Approval from UK for Tecovirimat

Retrieved on: 
Friday, July 8, 2022
European Medicines Agency, Research, GLOBE, Ix, COVID-19, Smallpox, EMA, Contract, Food, Biomedical Advanced Research and Development Authority, Monkeypox, Human services, BARDA, Vaccine, Patent, Vaccination, Regulation of tobacco by the U.S. Food and Drug Administration, Cowpox, FDA, Government, Exercise, Phrase, Xi, Development, Infection, Risk, Vii, Forward-looking statement, Documentation, CEO, Human, SIGA Technologies, Policy, Private Securities Litigation Reform Act, NASDAQ, Annual report, Assistant, Project Bioshield Act, United States Department of Health and Human Services, Health Canada, United Kingdom, Vaccinia, IV, Pharmaceutical industry

In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.

Key Points: 
  • In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.
  • SIGA Technologies, Inc.is a commercial-stage pharmaceutical company focused on the health security market.
  • Oral tecovirimat received approval from theEuropean Medicines Agency(EMA) in 2022.
  • The EMA approval includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Retrieved on: 
Thursday, June 23, 2022
Biomedical Advanced Research and Development Authority, Government, European Medicines Agency, Office of Inspector General, U.S. Department of Health and Human Services, Leadership, Forward-looking statement, Infection, Smallpox, Vii, Exercise, Monkeypox, SIGA Technologies, Documentation, Orthopoxvirus, Human services, GLOBE, Patent, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Phrase, CEO, Cowpox, Private Securities Litigation Reform Act, Vaccination, Policy, NASDAQ, Project Bioshield Act, Contract, Public health, FDA, COVID-19, BARDA, IV, Health Canada, LLC, Virus, Patient, Xi, Risk, US Foods, Vaccine, Human, Research, Meridian Medical Technologies Inc., Ix, Development, Vaccinia, EMA, Assistant, Military personnel, Pharmaceutical industry, Meridian

Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness, said Phil Gomez, CEO of SIGA.

Key Points: 
  • Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness, said Phil Gomez, CEO of SIGA.
  • The orders from the new international jurisdictions represent the first procurements of oral TPOXX (tecovirimat) directly in response to the evolving global monkeypox outbreak.
  • SIGA currently expects to deliver approximately $4 million of oral TPOXX (tecovirimat) under the two new contracts within the next 45 days.
  • With respect to the order from an existing customer, SIGA recently fulfilled the order by delivering $2 million of oral TPOXX (tecovirimat).

SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022

Retrieved on: 
Wednesday, June 22, 2022
Emergent BioSolutions, Biomedical Advanced Research and Development Authority, Monkeypox virus, European Medicines Agency, Office of Inspector General, U.S. Department of Health and Human Services, Forward-looking statement, Infection, Smallpox, Vii, Exercise, Monkeypox, SIGA Technologies, United Kingdom, U.S. Securities and Exchange Commission, Documentation, CDC, Human services, GLOBE, Cowpox, Patent, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Phrase, Private Securities Litigation Reform Act, Vaccination, Policy, NASDAQ, Project Bioshield Act, Contract, FDA, COVID-19, Poxviridae, Government, BARDA, IV, Xi, Vaccinia, Tonix Pharmaceuticals, Risk, Vaccine, Human, Research, Smallpox vaccine, Ix, Development, EMA, Assistant, Pharmaceutical industry, EU

The chat will be hosted by Alliance Global Partners and will also include representatives from Emergent Biosolutions and Tonix Pharmaceuticals.

Key Points: 
  • The chat will be hosted by Alliance Global Partners and will also include representatives from Emergent Biosolutions and Tonix Pharmaceuticals.
  • The FDA has not approved TPOXX for monkeypox in the US.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

Retrieved on: 
Thursday, May 19, 2022
Office of Inspector General, U.S. Department of Health and Human Services, Food, Ix, Exercise, Smallpox, Monkeypox, Contract, Government, Human services, Risk, Private Securities Litigation Reform Act, SIGA Technologies, Documentation, Annual report, HHS, Policy, Xi, Cowpox, COVID-19, Vaccination, Research, Patent, Immunization, GLOBE, CSO, Infection, Vaccine, IV, FDA, Biomedical Advanced Research and Development Authority, Human, Phrase, Assistant, Population, Regulation of tobacco by the U.S. Food and Drug Administration, Vaccinia, ASPR, Vii, NASDAQ, U.S. Department of Defense Strategy for Operating in Cyberspace, Forward-looking statement, Development, Project Bioshield Act, BARDA, Pharmaceutical industry

The IV formulation is an important option for those who are unable to swallow the oral capsules of TPOXX.

Key Points: 
  • The IV formulation is an important option for those who are unable to swallow the oral capsules of TPOXX.
  • We are grateful to the FDA for their work leading to approval of IV TPOXX, which will provide access to a broader patient population, said Dr. Dennis Hruby, CSO of SIGA.
  • The oral formulation of TPOXX (tecovirimat) is approved in the US, Canada and Europe for the treatment of smallpox.
  • The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018.